| |APRIL 20259TERBINAFINE HYDROCHLORIDE PRICES SET TO RISE AMID SUPPLY AND TRADE WOESASIA'S FIRST AI-DESIGNED LENS IMPLANT PERFORMED AT NETHRADHAMA HOSPITALThe pharmaceutical industry prepares for worldwide Terbinafine Hydrochloride price increases because of escalating market demand and distribution limitations together with global political challenges. Manufacturers intend to alter their pricing strategies because antifungal drug demand rises alongside inflation and labor costs increase which affects their profitability.February 2025 demonstrated a 7.5% growth in India's pharmaceutical market while Sanofi India and Ipca Laboratories along with Eris Lifesciences, JB Pharma, Mankind Pharma, Dr. Reddy's Laboratories and Cipla experienced a 9-16% surge in their sales records. The rising market demand suggests Terbinafine Hydrochloride prices may grow even more during March 2025.Donald Trump's proposed 25% blanket tariff plan against Indian pharmaceutical imports would affect markets all across the world because India positions as a major pharmaceutical exporter of Terbinafine Hydrochloride and other medications. The increase in tariffs will cause prices to rise throughout global markets, including the U.S. The shift of pharmaceutical companies toward other regions would reduce supply availability and raise costs throughout Europe alongside Asia-Pacific and other global markets.The implementation of these tariffs creates substantial threats to worldwide supply networks as well as pharmaceutical prices and market equilibrium stability. Some businesses look into supply chain relocations alongside supply chain expansions to minimize cost increases; however, these strategic changes require months to implement yet do not solve all pricing issues. The upward trend of operational costs and worsening trade relationships signals Terbinafine Hydrochloride will continue being expensive over the upcoming period. PONethradhama Super Speciality Eye Hospital in Bengaluru, a leader in eye care, has successfully carried out Asia's inaugural AI-designed intraocular lens implantation. Guided by Professor Dr. Sri Ganesh, Chairman & Managing Director of Nethradhama Super Speciality Eye Hospital and Founder Trustee of Shraddha Eye Care Trust, the hospital reached this achievement, making him the first surgeon in Asia to perform the procedure utilizing Rayner RayOne Galaxy and Galaxy Toric intraocular lenses (IOLs).This brings us closer to more individualized vision solutions by marking a noteworthy breakthrough in refractive cataract surgery and AI-driven vision correction. Patients with astigmatism and cataracts who want less reliance on glasses or total independence from them are the target market for these lenses. "For our patients, achieving true spectacle independence has always been a priority. They are particularly beneficial for individuals who require excellent vision across all distances while maintaining good night vision for driving and other low-light activities," noted Dr. Sri Ganesh.The first post-operative outcomes have been quite encouraging, according to Dr. Sri Ganesh, with patients reporting exceptional visual acuity in the first 24 hours. Long-term research will keep evaluating patient-reported experiences, he noted, especially in real-world scenarios like driving at night and in dimly lit areas. PO
< Page 8 | Page 10 >